Shu-Ping Chen, Kaohsiung City TW
Shu-Ping Chen, Kaohsiung City TW
Patent application number | Description | Published |
---|---|---|
20080269493 | Crystalline forms of topotecan hydrochloride and processes for making the same - Novel crystalline forms of topotecan hydrochloride and processes of making the same are disclosed. | 10-30-2008 |
20090012111 | Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin - A crystalline polymorph of 7-ethyl-10-hydroxycamptothecin exhibiting an X-ray diffraction pattern having peaks at 10.9±0.2, 13.2±0.2, 23.9±0.2, and 26.1±0.2 2-theta degree. | 01-08-2009 |
20090069584 | Levonorgestrel Crystallization - The present invention provides for a crystalline polymorph of levonorgestrel and processes for making the same. | 03-12-2009 |
20090076283 | Method of crystallizing carvedilol phosphate and the product thereof - The present invention provides for a crystalline polymorph of Carvedilol phosphate salt and a process for making the same. | 03-19-2009 |
20090275762 | Crystalline Forms of Docetaxel and process for Preparation Thereof - New anhydrous crystalline form of docetaxel and process of making anhydrous docetaxel and docetaxel trihydrate are provided. | 11-05-2009 |
20090326214 | Crystalline Polymorphs of Gemcitabine Base - The present application provides several crystalline forms of gemcitabine base and methods of making the same. | 12-31-2009 |
20100048613 | POLYMORPHIC FORM OF GRANISETRON HYDROCHLORIDE AND METHODS OF MAKING THE SAME - Crystalline granisetron hydrochloride characterized by a powder x-ray diffraction pattern with peaks at about 14.3, 20.4, and 23.0±0.2 degrees two-theta and process of making the same are disclosed. | 02-25-2010 |
20130237487 | CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS - The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5. | 09-12-2013 |